Psoriasis Clinical Trial

A Study to Evaluate the Safe and Effective Use of the Prefilled Safety Syringe or the Auto-injector for the Subcutaneous Self-injection of Bimekizumab Solution by Subjects With Moderate to Severe Chronic Plaque Psoriasis (PSO)

Summary

The purpose of the study is to evaluate the ability of subjects with moderate to severe chronic plaque psoriasis (PSO) to safely and effectively self-inject bimekizumab at study start and 8 weeks after training in self-injection technique using a prefilled safety syringe or an auto-injector.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Subject fulfills all inclusion criteria for the PS0014 [NCT03598790] study
Subject is considered reliable and capable of adhering to the DV0002 protocol (eg, able to understand and complete questionnaires, willing to self-inject, able to use investigational device according to the instructions for use (IFU), and able to adhere to the visit schedule) according to the judgment of the Investigator

Exclusion Criteria:

Subjects are not permitted to enroll in DV0002 if any of the PS0014 [NCT03598790] study exclusion criteria are met

Study is for people with:

Psoriasis

Phase:

Phase 3

Estimated Enrollment:

172

Study ID:

NCT03766685

Recruitment Status:

Completed

Sponsor:

UCB Biopharma SRL

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There are 27 Locations for this study

See Locations Near You

Dv0002 946
Phoenix Arizona, 85032, United States
Dv0002 910
Bakersfield California, 93309, United States
Dv0002 955
San Diego California, 92123, United States
Dv0002 943
San Luis Obispo California, 93405, United States
Dv0002 967
Santa Monica California, 90404, United States
Dv0002 906
Boca Raton Florida, 33486, United States
Dv0002 907
Miami Florida, 33144, United States
Dv0002 903
Ocala Florida, 34471, United States
Dv0002 936
Tampa Florida, 33624, United States
Dv0002 941
Alpharetta Georgia, 30022, United States
Dv0002 954
Skokie Illinois, 60077, United States
Dv0002 900
West Des Moines Iowa, 50265, United States
Dv0002 905
Overland Park Kansas, 66215, United States
Dv0002 962
Owensboro Kentucky, 42301, United States
Dv0002 922
Baton Rouge Louisiana, 70809, United States
Dv0002 925
Brighton Massachusetts, 02135, United States
Dv0002 917
Troy Michigan, 48084, United States
Dv0002 915
Saint Louis Missouri, 63117, United States
Dv0002 901
Portsmouth New Hampshire, 03801, United States
Dv0002 908
East Windsor New Jersey, 08520, United States
Dv0002 913
New York New York, 10029, United States
Dv0002 963
Rochester New York, 14623, United States
Dv0002 920
Portland Oregon, 97210, United States
Dv0002 929
Portland Oregon, 97223, United States
Dv0002 937
Johnston Rhode Island, 02919, United States
Dv0002 951
Houston Texas, 77598, United States
Dv0002 914
San Antonio Texas, 78213, United States
Dv0002 672
Edmonton , , Canada
Dv0002 673
Halifax , , Canada
Dv0002 671
Hamilton , , Canada
Dv0002 675
Markham , , Canada
Dv0002 663
Mississauga , , Canada
Dv0002 660
Montréal , , Canada
Dv0002 665
Québec City , , Canada
Dv0002 651
Richmond Hill , , Canada
Dv0002 653
Toronto , , Canada
Dv0002 662
Toronto , , Canada
Dv0002 657
Waterloo , , Canada
Dv0002 670
Windsor , , Canada

How clear is this clinincal trial information?

Study is for people with:

Psoriasis

Phase:

Phase 3

Estimated Enrollment:

172

Study ID:

NCT03766685

Recruitment Status:

Completed

Sponsor:


UCB Biopharma SRL

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.